- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04088643
4Hz Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease
July 12, 2022 updated by: Xuanwu Hospital, Beijing
The Efficacy of 4Hz Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease: A Randomized Controlled Clinical Trial
The goal of this study is to explore the efficacy and safety of 4Hz transcranial alternating current stimulation (tACS) in patients with mild Alzheimer's disease (AD).
The study will recruit 40 individuals with mild AD, and the participants will be randomized to either a 4 Hz tACS group or a sham stimulation group.
Both groups will undergo 30 one-hour sessions across 3 weeks (21 days).
At the end of the intervention and 3-month follow-up, all subjects will repeat the baseline assessments.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Background: Recently, transcranial alternating current stimulation (tACS), which could interact with ongoing neuronal activity, has emerged as a potentially effective and promising treatment for Alzheimer's disease (AD), and the 4Hz frequency was suggested to improve working memory Methods: The proposed study is a double-blinded, randomized controlled trial that will include 40 individuals with mild AD, and the participants will be randomized to either a 4Hz tACS group or a sham stimulation group.
Both groups will undergo 30 one-hour sessions in 3 weeks (21 days).
The outcome measures will be assessed at baseline, end of intervention and 3 months after the first session.
Primary outcome is global cognitive function, assessed by the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), and the second outcomes include changes in other neuropsychological assessments, structural MRI, resting electroencephalogram (EEG) and simultaneous EEG-functional MRI (fMRI).
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100053
- Xuanwu Hospital, Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with informed consent;
- 45-75 years of age;
- At least 6 years of education;
- AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) guidelines;
- Clinical Dementia Rating Scale (CDR)=1.0;
- Positive findings in amyloid PET imaging or amyloid protein levels in CSF;
- On a stable dose of cholinesterase inhibitors (e.g. donepezil or rivastigmine) as defined as 6 consecutive weeks of treatment at an unchanging dose, and without any intentions to modify the dosage during the observation period.
Exclusion Criteria:
- Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis), poorly controlled migraines or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment;
- Contraindication for undergoing MRI or receiving tACS;
- Eczema or sensitive skin;
- Familial AD;
- Depression or other psychiatric disorders;
- Abnormal brain structural magnetic resonance imaging (MRI) scan, including hydrocephalus, stroke, structural lesions, etc. that would potentially confound the outcome;
- Severe cardiovascular/pulmonary disorders;
- Other conditions, in the investigator's opinion, might not be suitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: sham stimulation group
Sham stimulator provided by NEXALIN company
|
Electrodes will also be put on patient's forehead and behind each ear.
The sham stimulator has the exactly same appearance with the true stimulator.
Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings.
However, when the device is started, no current flows through the electrodes.
Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
|
Experimental: tACS group
NEXALIN ADI transcranial alternating current stimulator
|
The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology.
The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables.
Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version)
Time Frame: up to 21 days (end of intervention)
|
ADAS-cog 11 scale ranges from 0 to 70, and higher value represents a worse outcome.
This study will use ADAS-cog to assess changes in the global cognitive function after intervention.
|
up to 21 days (end of intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version).
Time Frame: 3 months
|
ADAS-cog 11 scale ranges from 0 to 70, and higher value represents a worse outcome.
This study will use ADAS-cog to assess changes in the global cognitive function after intervention.
|
3 months
|
Change in brain volume and white matter integrity
Time Frame: up to 21 days (end of intervention), 3 months
|
Structural MRI will be used to measure brain volume and white matter integrity.
|
up to 21 days (end of intervention), 3 months
|
Change in brain connectivity
Time Frame: up to 21 days (end of intervention), 3 months
|
Functional MRI and resting-state EEG will be used to measure brain connectivity.
|
up to 21 days (end of intervention), 3 months
|
Change in Mini-mental State Examination
Time Frame: up to 21 days (end of intervention), 3 months
|
Mini-mental State Examination (MMSE) will be used to evaluate the general cognitive function.
MMSE ranges from 0 to 30, and higher value represents a better outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Montreal Cognitive Assessment
Time Frame: up to 21 days (end of intervention), 3 months
|
Montreal Cognitive Assessment (MoCA) will be used to evaluate the general cognitive function.
MoCA ranges from 0 to 30, and higher value represents a better outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Clinical Dementia Rating Scale sum of the boxes
Time Frame: up to 21 days (end of intervention), 3 months
|
Clinical Dementia Rating Scale sum of the boxes (CDR-SB) will be used to evaluate the general cognitive function.
CDR-SB ranges from 0 to 18, and higher value represents a worse outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in memory function
Time Frame: up to 21 days (end of intervention), 3 months
|
WHO-UCLA Auditory Verbal Learning Test will be used to assess memory function.
It ranges from 0 to 45, and higher value represents a better outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Digit span forward
Time Frame: up to 21 days (end of intervention), 3 months
|
Digit span will be used to assess attention.
It ranges from 3 to 10, and higher value represents a better outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Digit span backward
Time Frame: up to 21 days (end of intervention), 3 months
|
Digit span backward will be used to assess executive function.
It ranges from 2 to 8, and higher value represents a better outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Trail Making Test
Time Frame: up to 21 days (end of intervention), 3 months
|
Trail-Making Test B minus A score will be used to assess executive function.
Trail-Making Test B minus A ranges from -150 to 300, higher value represents a worse outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Boston Naming Test
Time Frame: up to 21 days (end of intervention), 3 months
|
Boston Naming Test will be used to assess language function.
It ranges from 0 to 30, and higher value represents a better outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Neuropsychiatric Inventory (NPI)
Time Frame: up to 21 days (end of intervention), 3 months
|
The Neuropsychiatric Inventory will be used to measure neuropsychiatric symptoms.
It ranges from 0 to 144, and higher value represents a worse outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Geriatric Depression Scale (GDS)
Time Frame: up to 21 days (end of intervention), 3 months
|
The Geriatric Depression Scale will be used to measure neuropsychiatric symptoms.
It ranges from 0 to 30, and higher value represents a worse outcome.
|
up to 21 days (end of intervention), 3 months
|
Change in Activities of Daily Living
Time Frame: up to 21 days (end of intervention), 3 months
|
Activities of Daily Living (ADL) scale will be used to assess the change of life quality.
It ranges from 20 to 80.
The "20" represents normal life ability and the higher score presents the worse life ability.
|
up to 21 days (end of intervention), 3 months
|
Side-effects of tACS
Time Frame: up to 21 days (end of intervention), 3 months
|
Adverse Events as a result of tACS stimulation will be reported.
|
up to 21 days (end of intervention), 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yi Tang, M.D., Ph.D., Xuanwu Hospital, Beijing
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 14, 2019
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
September 11, 2019
First Submitted That Met QC Criteria
September 11, 2019
First Posted (Actual)
September 13, 2019
Study Record Updates
Last Update Posted (Actual)
July 13, 2022
Last Update Submitted That Met QC Criteria
July 12, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018077
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on sham stimulation
-
National Cheng-Kung University HospitalRecruiting
-
Georgia Institute of TechnologyEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsNot yet recruiting
-
Sheba Medical CenterSuspended
-
Tianjin Anding HospitalChinese Academy of SciencesEnrolling by invitationSchizophrenia Negative TypeChina
-
Beijing Tiantan HospitalPeking Union Medical College Hospital; China-Japan Friendship Hospital; The First...Unknown
-
Mary Phillips, MD MD (Cantab)National Institute of Mental Health (NIMH)RecruitingBipolar DisorderUnited States
-
Dr. med. Carlo CeredaUniversity Hospital Inselspital, Berne; CLINICA HILDEBRAND CENTRO DI RIABILITAZIONE... and other collaboratorsUnknownIschemic Stroke | First Ever Clinical Stroke | Subacute Phase | Persistent Hemiparesis of Upper ExtremitySwitzerland
-
Christian BaumannETH ZurichRecruitingParkinson Disease | Mild Cognitive Impairment | Huntington DiseaseSwitzerland
-
University of PittsburghCompleted
-
University of BonnRecruiting